A bdominal aortic aneurysm (AAA) is a common vascular degenerative disease with a high risk of sudden death, particularly in elderly people. It has been estimated that >70 000 people >65 years of age died of AAA annually. Surgical repair remains the treatment of choice in patients with a large AAA. However, a lack of effective medications constitutes a major limitation to the treatment of patients with small AAAs or contradictions to surgery, and more extensive research is required to develop novel pharmaceutical therapies for AAA.
In experimental studies, a widely accepted animal model of AAA is chronic infusion of angiotensin II (Ang II) in apolipoprotein E-knockout (ApoE −/− ) mice, which shares many pathological similarities with human AAA. Ang II is the main effector hormone of the rennin-angiotensin system that induces chronic inflammation, matrix degradation, and vascular remodeling of the abdominal aorta. Recent research in our laboratory has revealed that Ang (1-7), which is cleaved from Ang II by angiotensin-converting enzyme 2, 1 counteracts the detrimental effects of Ang II in atherosclerosis and diabetic cardiomyopathy.
2,3 Angiotensin-converting enzyme 2 and Ang (1-7) as a promising therapeutic target in cardiovascular disease has been systemically reviewed recently. 4 However, other peptides of rennin-angiotensin system that are directly hydrolyzed from Ang II have received little attention. For instance, Ang (2) (3) (4) (5) (6) (7) (8) , also known as Ang III, is a degradation product of Ang II by aminopeptidase A and were reported to share similar effects with Ang II on the regulation of blood pressure and renal function. [5] [6] [7] Ang (3-8), also known as Ang IV, which is hydrolyzed from Ang II by dipeptidylaminopeptidase III or from Ang III by aminopeptidase N, 5 was found to increase blood flow in the central nervous system and contributed to improve learning skill and memory. 8 As well, chronic Ang IV infusion improved endothelial function in early and advanced atheroma.
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September 2015 vascular smooth muscle cells (SMCs), 11 suggesting a harmful effect mimicking Ang II. Therefore, the exact role of Ang IV in vascular diseases remains obscure and the mechanism underlying its contradictive effects is poorly understood. Hereto, the effect of Ang IV on Ang II-induced AAA models has not been reported in the literature. In this study, we sought to explore the therapeutic effects of Ang IV on Ang II-induced AAA in ApoE −/− mice and elaborate the possible mechanism mediating these effects.
Methods
Detailed material and methods are available in the online-only Data Supplement.
Results

Serum Lipid Levels and Blood Pressure
Serum lipid levels did not differ among all animal groups (Tables S1 and S2 in the online-only Data Supplement). Ang II infusion significantly increased systolic blood pressure (SBP) in ApoE −/− mice compared with SBP measured at baseline or in the control group. However, neither Ang IV at different doses nor divalinal-Ang IV had effect on SBP.
A total of 617 SBP measurements (points) were obtained with radiotelemetry and tail-cuff techniques. These points scattered around a linear regression line with a slope of 0.85 and r 2 of 0.55, suggesting a moderate correlation between the 2 techniques ( Figure S1A ). Bland-Altman analysis also indicated a good agreement in SBP between the 2 techniques but there was a systemic 4.6 mm Hg underestimation of radiotelemetry-derived SBP by tail-cuff technique ( Figure S1B ). In addition, a total of 246 SBP measurements were obtained with Millar catheter and tail-cuff techniques. The r 2 value of a linear regression between the 2 techniques was 0.85, and the slope was 1.02 ( Figure S1C ). Bland-Altman analysis revealed a good agreement in SBP between the 2 techniques but with a systemic overestimation of 6.5 mm Hg in Millar catheter-derived SBP by tail-cuff technique ( Figure S1D ).
Effect of Ang IV Treatment on the Incidence of AAA in Ang II-Infused Mice
The incidence of AAA was 87.5%, 66.7%, 37.5%, and 83.3% in the no treatment, low-dose Ang IV, medium-dose Ang IV, and high-dose Ang IV groups, respectively, with no mice in the control group developing AAA (0%, Figure 1B ). Compared with the no treatment group, the incidence of AAA was substantially decreased in the medium-dose Ang IV group ( Figure 1A and 1B) but not in the low-dose and high-dose Ang IV groups. As well, the maximal diameter of the abdominal aorta was significantly reduced in the medium-dose Ang IV Figure 1D ) but not in the low-dose and high-dose Ang IV groups in comparison with the no treatment group. Highdose Ang IV treatment reversed the decline of AAA incidence and the decrease of maximal aortic diameter caused by medium-dose Ang IV treatment.
In the absence of Ang II stimulation, however, treatment with low-, medium-, and high-dose Ang IV alone neither induced AAA formation nor increased the maximal abdominal aortic diameters in ApoE −/− mice ( Figure S2 ). 
Effect of
Mouse Aortas
Hematoxylin and eosin and Verhoff-Van Gieson staining revealed that Ang II infusion caused positive remodeling of the abdominal aorta, breakdown of the aortic media and adventitia, hypertrophy of the adventitia, and destruction and discontinuity of elastin fibers in ApoE −/− mice. Compared with the no treatment group, these pathological changes induced by Ang II were largely attenuated in the low-dose and mediumdose Ang IV groups ( Figures 1C and 2A) . However, the morphology of the abdominal aorta was similar in no treatment and high-dose Ang IV groups, which was characterized by a dilated abdominal aorta, elastin fiber breakdown and discontinuity, aortic wall thickening, and intraluminal thrombosis.
Specifically, the relative contents of collagen and SMCs in the aortic wall were substantially increased in the low-dose and medium-dose Ang IV groups, whereas the content of macrophages was decreased in the medium-dose Ang IV group relative to the no treatment group (Figure 2A-2D ). In contrast, these parameters showed only insignificant difference between the no treatment and high-dose Ang IV groups, and high-dose Ang IV treatment reversed the effect of mediumdose Ang IV on collagen, SMCs, and macrophages.
Effect of Ang IV on the Expression of Proinflammatory Cytokines
As chronic inflammation of the aortic wall is a main feature of AAA, we examined the expression of proinflammatory cytokines, such as monocyte chemoattractant protein 1, interleukin 6 (IL-6), and intercellular adhesion molecule 1 (ICAM-1), which were found to be upregulated in Ang II-infused ApoE −/− mice. 12, 13 Both immunostaining and Western blot analysis showed that the protein expression level of monocyte chemoattractant protein 1, IL-6, and ICAM-1 in aortic tissues was significantly attenuated by medium-dose Ang IV treatment relative to the no treatment group and the expression level of IL-6 and ICAM-1 showed similar changes by low-dose Ang IV treatment ( Figure 3A and 3D-3F; Figure S3A and S3C). In contrast, high-dose Ang IV treatment did not affect the expression of these proinflammatory cytokines compared with the no treatment group, but it reversed the effect of medium-dose Ang IV. In vitro study showed that a low dose (10 -9 mol/L) of Ang IV exhibited a similar antagonistic pattern against Ang II-induced upregulation of monocyte chemoattractant protein 1, IL-6, and ICAM-1 in human aortic SMCs (hASMCs) as in vivo study ( Figure  S4D and S4G-S4I), whereas the high dose (10 -5 mol/L) reversed the effect of the low-dose Ang IV on inflammatory cytokine expressions. Thus, Ang IV treatment with an optimal dose may attenuate Ang II-induced inflammation both in vivo and in vitro.
Ang IV Modulated the Expression of Extracellular Matrix -Related Proteins
To assess the effect of Ang IV on extracellular matrix homeostasis, we examined the expression of type I and III collagen and matrix metalloproteinase (MMP)-2 and MMP-9 in mice. Compared with no treatment group, medium-dose Ang IV significantly increased collagen deposition in aorta, and low-dose Ang IV only obviously increased type III collagen expression in aorta, whereas high-dose Ang IV had no such an effect ( Figure 2B and 2E-2G). In addition, medium-dose Ang IV significantly decreased both the protein expression level and activity of MMP-2 and MMP-9 in aortic tissues, whereas high-dose Ang IV did not ( Figure 3A -3C and 3G-3I; Figure S3A and S3B). In hASMCs, low-dose Ang IV dramatically blunted Ang II-induced downregulation of collagen and upregulation of MMPs ( Figure S4A-S4F) , and high dose obviously reversed the effect of low-dose Ang IV stimulation.
Akt and NF-κB Signaling Were Involved in the Effect of Ang IV on Ang II-Induced AAA To verify the signaling proteins involved in the Ang IV effect, we examined the expression level of Akt and NF-κB both in vivo and in vitro. In medium-dose Ang IV-treated mice and 10 -9 mol/L Ang IV-treated hASMCs, phosphorylated Akt production was significantly increased and NF-κB expression was decreased compared with the no treatment group of mice and cells, respectively (Figure 4A-4C ; Figure S4M -S4O). High-dose Ang IV did not markedly affect the phosphorylation of Akt and the expression of NF-κB in vivo or in vitro. To further study the role of Akt in the protective effect of Ang IV, we used the Akt inhibitor A6730 to cotreat hASMCs. Blunted Akt signaling eliminated the suppression of inflammation and MMP-2 expression by Ang IV, and diminished Ang IV-induced upregulation of collagen, although it did not have effect on MMP-9 expression ( Figure 5 ). Therefore, Akt may have a crucial role in the protective effect of Ang IV on Ang II-induced AAA.
Ang IV Altered the Expression of Different Types of Ang Receptors
We then investigated the expression of different angiotensin receptor subtypes involved in the bidirectional effect of Ang IV on Ang II-induced AAA in vivo. As compared with the no treatment group, medium-dose Ang IV significantly Figure 4D-4J ). When compared with the medium-dose Ang IV group, however, high-dose Ang IV treatment induced a significant increase in the mRNA and protein expression of AT 1 R, while it caused a significant decrease in the mRNA expression of AT 4 R and an obvious decrease in the protein expression of AT 4 R and AT 2 R. The results in vitro showed that relative to the no treatment group, the mRNA expression of AT 1 R was decreased in both lowdose (10 −9 mol/L) and medium-dose (10 −7 mol/L) Ang IV groups, and the protein expression of AT 1 R was decreased only in lowdose Ang IV group ( Figure S4J -S4L, S4M, and S4P). In contrast, the mRNA expression of AT 2 R and AT 4 R were increased in lowdose Ang IV group, whereas the protein expression of AT 2 R and AT 4 R was increased in both low-dose and medium-dose Ang IV groups ( Figure S4M 
High-Dose Ang IV Mimicked the Effects of Ang II via AT 1 R
In hASMCs receiving different doses of Ang IV treatment without Ang II stimulation, there was a dose-dependent and significant increase in the mRNA expression of AT 1 R from the control group to the medium-dose and the high-dose Ang IV groups ( Figure S7A ).
Similar to the effect of Ang II, high-dose Ang IV alone significantly decreased the expression of type I and III collagen and increased the expression of MMPs and proinflammatory cytokines ( Figure S8 ). Notably, these effects of high-dose Ang IV were blocked by AT 1 R antagonist losartan.
Monitoring of Serum Ang IV Concentration in ApoE −/− Mice
There was no significant difference in the serum Ang IV concentration between the control and the no treatment groups. However, the serum Ang IV concentration was remarkably higher in the medium-dose Ang IV group than in the control or no treatment groups ( Figure S7B ).
Discussion
In this study, we demonstrated that Ang IV had a bidirectional effect on Ang II-induced AAA in ApoE −/− mice. Mediumdose Ang IV significantly reduced the incidence and severity of AAA and inhibition of AT 4 R largely reversed the protective effect of Ang IV. The mechanisms underlying these salutary effects included decreased MMPs expression and activity, increased SMC and collagen content and inhibited inflammation via activated Akt and blunted NF-κB signaling. In contrast, high-dose Ang IV did not have obvious beneficial effect and the mechanism may involve variable angiotensin receptor stimulation, that is, Ang IV may act as an inverse agonist of AT 1 R at a high dose. To the best of our knowledge, this is the first study in the literature to report the bidirectional effect of Ang IV on AAA and the potential mechanism involved.
In this study, we used 3 different doses of Ang IV (0.72 mg/kg per day, 1.44 mg/kg per day, and 2.88 mg/kg per day), prolonged the treatment time to 28 days, and found that the medium-dose Ang IV substantially attenuated the incidence and severity of Ang II-induced AAA, whereas high-dose Ang IV did not have protective effect against Ang II. These results demonstrate that the effect of Ang IV on AAA is dose-dependent and bidirectional and an optimal dose of Ang IV is required for the treatment of AAA.
One important finding of this study is that the therapeutic effect of Ang IV is independent of lipid profile and blood pressure. The serum lipid levels were not significantly different among all mouse groups, and none of the 3 doses of Ang IV lowered Ang II-elevated SBP, which was consistent with previous studies. 9, 10 In an attempt to verify the accuracy of SBP measurements by tail-cuff method, we compared the SBP values derived from tail-cuff, radiotelemetry, and Millar catheter methods, and found a good agreement between tailcuff and radiotelemetry or Millar catheter techniques, which was in line with a previous report.
14 In addition, previous studies elegantly demonstrated that blood pressure did not play a major role in AAA formation in Ang II-stimulated ApoE −/− mice. 15, 16 Therefore, the effect of Ang IV on AAA was blood pressure-independent.
To examine the possibility that exogenously infused Ang II may be cleaved into Ang IV in the mouse circulation, the serum Ang IV concentration was monitored in this study. To our surprise, no significant difference in the serum Ang IV concentration was found between the control and the no treatment groups, and the reason for this may be because of the fact that angiotensin peptides have a short half-life (10-20s), 17, 18 and it takes several steps for Ang II to be converted to Ang IV. Thus, only a constant infusion of Ang IV can keep a high serum Ang IV concentration as shown in the mediumdose Ang IV group.
Chronic inflammation characterized by enhanced infiltration of inflammatory cells and overexpression of proinflammatory cytokines, 12, 13 has been considered an instigating mechanism underlying Ang II-induced AAA. 13 In this study, medium-dose Ang IV treatment markedly reduced macrophage accumulation in AAA tissues and significantly decreased the expression of proinflammatory cytokines, such as monocyte chemoattractant protein 1, IL-6, and ICAM-1. However, with high-dose Ang IV treatment, these beneficial effects were diminished. Similar results were obtained in vitro. These results suggest that the bidirectional effect of Ang IV on AAA was associated with their different impact on the extent of inflammation in the aortic wall.
Excessive degradation of extracellular matrix and positive remodeling of the aortic wall are main pathological features of human AAA. 19 The initial event of AAA is the destruction of the medial elastic lamellae, mediated mainly by MMPs. In particular, the expression and activity of MMP-2 and MMP-9 are increased in human AAA, which are crucial to the formation of AAA. 20 In our study, we found that medium-dose Ang IV markedly increased collagen deposition in AAA by suppressing the expression and activity of MMP-2 and MMP-9, thus preserving the vascular integrity in ApoE −/− mice, whereas high-dose Ang IV did not have such a prohibitive effect on MMPs.
Akt signaling has multifunctional effects on cellular metabolism, survival, proliferation, and migration. 21 However, the expression and activation of Akt were prohibited in human aortic aneurysmal tissues and knockout of Akt-2 deteriorated Ang II-induced AAA. 22 NF-κB is an important transcriptional factor that mediates the expression of many proinflammatory cytokines and can be activated by Ang II. In this study, mediating these effects. However, high-dose Ang IV had a contrasting impact on Akt and NF-κB, which may explain the worsening effect of high-dose Ang IV on the formation of AAA in ApoE −/− mice. It is well known that the effect of angiotensins is receptor-mediated. Our result showed that medium-dose Ang IV treatment in ApoE −/− mice was associated with significantly increased expression of AT 4 R and AT 2 R, and decreased expression of AT 1 R, suggesting that AT 4 R and AT 2 R were stimulated, whereas AT 1 R was suppressed by medium-dose Ang IV. AT 4 R, also known as the enzyme insulin-regulated aminopeptidase, provides a high-affinity binding site for Ang IV. 23 Previous studies reported that Ang IV functioned by directly binding to AT 4 R or inhibiting this enzyme. 24, 25 In this study, we found that administration of divalinal-Ang IV, an antagonist of AT 4 R, reversed most but not all the beneficial effects of medium-dose Ang IV in vivo. This is probably because of the fact in the low-to medium-dose range, Ang IV stimulates both AT 4 R and AT 2 R, as evidenced by the increased expression of AT 4 R and AT 2 R after low-to medium-dose Ang IV treatment. Administration of divalinal-Ang IV can block only AT 4 R, whereas Ang IV can still bind AT 2 R and exert its physiological effects. Our results lent support to previous studies showing that Ang IV caused AT 2 R-mediated vasodilation in the resistance arteries and isolated lungs of rats, 26, 27 and AT 2 R antagonist PD123319 markedly reversed the superoxide reduction evoked by Ang IV in ApoE −/− mice. 9 This doublereceptor stimulation phenomenon is similar to other angiotensins, such as Ang II that binds both AT 1 R and AT 2 R, and Ang-(1-7) that binds both Mas receptor and AT 2 R. 4 A critical question raised by this study is why the therapeutic effect of Ang IV at the medium dose was abolished when a high dose of Ang IV was administered. Our studies in vivo and in vitro consistently demonstrated that compared with the low-or medium-dose Ang IV, high-dose Ang IV-induced significantly higher expression of AT 1 R and lower expression of AT 4 R and AT 2 R. More importantly, our results in vitro revealed that when the dose of Ang IV increased to 10 −5 mol/L in the high-dose Ang IV group, a dose 100× the preinjected dose of Ang II (10 −7 mol/L), the expression of AT 4 R and AT 2 R began to decrease and that of AT 1 R began to increase. Although our experiments in vitro found that Ang IV dose-dependently increased mRNA expression of AT 1 R, and high-dose Ang IV (10 −5 mol/L) treatment mimicked the effect of Ang II (10 −7 mol/L) via AT 1 R, our studies in vivo did not demonstrate that high-dose Ang IV-induced AAA formation, suggesting that the high-dose Ang IV used in vivo (2.88 mg/kg per day) was still too low relative to the dose of Ang II (1.44 mg/kg per day). This may explain why high-dose Ang IV treatment only showed a lack of beneficial effects on AAA but did not further aggregate the severity of AAA in our study. These results were highly consistent with a previous report showing that in glomerular mesangial cells, Ang IV competitively binded to renal AT 1 R at a concentration 10-to 100-fold higher than that of Ang II, and in renal cortex autoradiography, the inhibitory potency (IC50) on AT 1 R binding for Ang II and Ang IV was 3.8±0.3 nmol/L and 300±15 nmol/L, respectively. 28 Structurally, Ang IV possesses 3 NH2-terminal amino acids (Asp 1 -Arg 2 -Val 3 ), which are important for pressor activity of Ang II, 29 indicating that Ang IV may act as a weak agonist of AT 1 R. These results suggested a novel variable receptor stimulation mechanism: Ang IV stimulates AT 4 R and AT 2 R at a low or medium dose and switches to stimulation of AT 1 R at a high dose. However, the detailed mechanism requires further investigation.
Conclusions
Ang IV exerted a dose-dependent bidirectional effect on Ang II-induced AAAs in ApoE −/− mice. Ang IV at a medium dose provided protection against Ang II-induced AAA by inhibiting inflammatory response and MMP activity via stimulation of AT 4 R and AT 2 R, activation of Akt and suppression of NF-κB signaling. High-dose Ang IV abolished these salutary effects possibly by a switched stimulation of AT 1 R. Thus, medium-dose Ang IV may provide a novel and promising target for the treatment of AAA.
Perspectives
Currently, the pathogenetic mechanism of AAA remains unclear and surgical repair is the only choice of treatment in patients with a large AAA. Thus, a pharmacological approach to AAA is highly warranted. Our results clearly demonstrated that Ang IV at a medium dose provided protection against Ang II-induced AAA by inhibiting inflammation and MMP activity via stimulation of AT 4 R and AT 2 R, activation of Akt and suppression of NF-κB signaling. Thus, optimal dose Ang IV may provide a promising approach to the treatment of AAA in the future. Therefore, our findings have important clinical implications.
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What Is New?
• Angiotensin IV (Ang IV) had a dose-dependent bidirectional effect on Ang II-induced abdominal aortic aneurysm (AAA) in apolipoprotein E-knockout (ApoE −/− ) mice, and medium-dose Ang IV could protect against Ang II-induced AAA. The potential mechanism underlying these beneficial effects may involve declined inflammatory response and matrix metalloproteinase activity via stimulation of AT 4 R and AT 2 R, activation of Akt and suppression of nuclear factor-κB signaling. High-dose Ang IV abolished these salutary effects possibly by a switched stimulation of AT 1 R.
What Is Relevant?
• Currently, the pathogenetic mechanism of AAA is still unclear and surgical repair is the only choice of treatment in patients with a large AAA.
Thus, a pharmacological approach to AAA is highly warranted. Our results clearly demonstrated that Ang IV with an optimal dose attenuated Ang II-induced AAA in ApoE −/− mice and these salutary effects were probably mediated by stimulation of AT 4 R and AT 2 R and activation of Akt. Thus, an optimal dose of Ang IV may provide a promising approach to the treatment of AAA in the future.
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The ) mice aged 6-8 weeks on a C57BL/6J background were purchased from Beijing Huafukang Animal Experimental Center. All mice were kept on a 12-hr light/12-hr dark cycle with food and water freely available, and were fed on a high-fat diet (0.25% cholesterol and 15% cocoa butter) for 8 weeks.
In the first part of the in vivo study, in order to examine the dose-effect of angiotensin IV (Ang IV) on Ang II-induced abdominal aortic aneurysm (AAA), mice were randomly divided into 5 groups after a 4-week high-fat diet feeding (n=20 per group), and were treated with continuous subcutaneous infusion of different agents via an osmotic pump (Alzet model 2004, Alza Corp., Palo Alto, CA, USA) for 28 days. The control group received infusion of saline, the no treatment group received infusion of only Ang II (1.44 mg/kg per day, Lintai Biological Technology Company, Xi'an, China), the low-dose Ang IV group received infusion of Ang II (1.44 mg/kg per day) plus Ang IV (0.72 mg/kg per day, Lintai Biological Technology Company, Xi'an China), the medium-dose Ang IV group received infusion of Ang II (1.44 mg/kg per day) plus Ang IV (1.44 mg/kg per day), and the high-dose Ang IV group received infusion of Ang II (1.44 mg/kg per day) plus Ang IV (2.88 mg/kg per day) 1, 2 . All mice underwent euthanasia after 28-day infusion and the aortic tissues were extracted for further investigation.
In the second part of the in vivo study, in order to elaborate the role of type 4 Ang receptor (AT 4 R) in the effect of Ang IV on Ang II-induced AAA, sixty mice were randomly divided into 3 groups (n=20 per group): a no treatment group that received infusion of only Ang II (1.44 mg/kg per day), a medium-dose Ang IV group that received infusion of Ang II (1.44 mg/kg per day) plus Ang IV (1.44 mg/kg per day), a divalinal-Ang IV group that received infusion of Ang II (1.44 mg/kg per day) plus Ang IV (1.44 mg/kg per day) and AT 4 R antagonist divalinal-Ang IV (1.44mg/kg per day, Lintai Biological Technology Company, Xi'an, China). These agents were continuously infused into mice subcutaneously via an osmotic pump for 28 days and then the aortic tissues were extracted from all mice after euthanasia.
In the third part of the in vivo study, in order to acquire a full assessment of the effects of different doses of Ang IV alone on AAA formation in the absence of Ang II, eighty mice were randomly divided into 4 groups (n=20 per group): the control group, the low-dose Ang IV group, the medium-dose Ang IV group and the high-dose Ang IV group, receiving infusion of saline and different doses of Ang IV (0.72 mg/kg per day, 1.44 mg/kg per day and 2.88 mg/kg per day), respectively, via an osmotic pump for 28 days.
Blood pressure measurement
Systolic blood pressure (SBP) was measured by a pulse based tail-cuff method with a photoelectric device (Natsume, Tokyo, Japan) every week in all mice after initiation of the experiment. Blood pressure was reported as a mean of 3 consecutive measurements.
To examine the accuracy of SBP by noninvasive tail-cuff technique, SBP was measured simultaneously by radiotelemetry (HD-X11 Transmitter, Data Sciences International, St Paul, MN) and tail-cuff in 7 conscious mice, and by a Millar catheter (SPR-869，Millar Instruments Inc., Houston, TX) and tail-cuff in 4 Wistar rats after anesthesia. The protocol for SBP measurement using telemetry technique was concordant with previous reports 3 . In brief, after anesthesia, the catheter of the telemetric transducer was inserted into the left common carotid artery of mice and advanced to the thoracic aorta, and the body of the transducer was secured in a subcutaneous pouch along the right flank of the mice through the same ventral neck incision. All mice were allowed to recover from surgery for 1 week before SBP measurement. Transient blood pressure elevation was induced by Ang II injection (0.5μg/g, every 2 hr). Blood pressure measurements were acquired simultaneously with telemetry and tail-cuff device.
For measurement of blood pressure with Millar catheter technique, rats were placed on a heat-controlled operating pad after anesthesia to maintain body temperature. A midline incision was made overlying the trachea down to the xyphoid bone. A Millar SPR-869 microtip catheter was inserted into the right common carotid artery and advanced into the aorta 4 . Transient blood pressure elevation was induced by Ang II injection (0.5μg/g, every half an hour) 5 . Blood pressure was recorded simultaneously by Millar catheter and tail-cuff techniques under anesthesia. Biochemical studies Fasting blood samples of mice were collected before euthanasia. Serum concentrations of total cholesterol, triglycerides, low-density lipoprotein cholesterol and high-density lipoprotein cholesterol were determined by a commercially available enzymatic assay using a biochemistry automatic analyzer (HITACHI 7170A, Hitachi, Tokyo, Japan).
AAA quantification
After exsanguination and saline perfusion of ApoE -/-mice, the aortas were removed and fixed in 4% paraformaldehyde overnight. The adventitia was removed the next day, and the maximal diameter of the abdominal aorta was measured by use of Image-Pro Plus 6.0 (Media Cybernetics, USA) for aneurysm quantification. AAA was defined as ≥ 50% enlargement of the external diameter of the abdominal aorta as compared with the control group 6 . Two independent individuals blinded to the experiment were responsible for the measurement of abdominal aortas.
Histology and morphology
Aortic segments from the aortic arch to the renal arteries were removed and embedded in OCT compound, and serial cross cryosections (5 μm thick) from the proximal to the distal region of the aneurysm were prepared for histological and morphological analysis.
Aortic sections of different groups were stained by hematoxylin and eosin for morphologic assessment. Elastic fiber integrity of the abdominal aorta was visualized by use of a Verhoeff-Van Gieson staining kit (Gemed Scientific Inc., USA) according to manufacturer's instruction. Masson's trichrome staining was used for examination of the aortic collagen content.
Immunohistochemical staining
Immunohistochemic staining was performed to measure the relative content of macrophages (Anti-Monocyte + Macrophage antibody, MOMA-2, diluted 1:100, AbD Serotec, UK), smooth muscle cells (SMCs, α SM-actin, diluted 1:200, Abcam, UK), matrix metalloproteinase 2 (MMP-2, diluted 1:100, Abcam, Hong Kong; or diluted 1:100, Proteintech Group, USA), MMP-9 (diluted 1:100, Abcam, Hong Kong; or diluted 1:100, Proteintech Group, USA), monocyte chemoattractant protein 1 (MCP-1, diluted 1:100, Abcam, Hong Kong; or diluted 1:50, Proteintech Group, USA) and interleukin 6 (IL-6, diluted 1:100, Abcam, Hong Kong; or diluted 1:200, Proteintech Group, USA) in tissue sections of AAA. Immunoreactivity was visualized after incubation with the appropriate horseradish peroxidase-conjugated secondary antibodies and then with 3', 3'-diaminobenzidine.
The ratios of the positive staining area of macrophages, SMCs, MMP-2, MMP-9, MCP-1 and IL-6 to the aortic cross sectional area were calculated by use of Image-Pro Plus 6.0 respectively. Appropriate negative controls using isotype Ig G were applied. Cell culture and treatment Human primary aortic SMCs (hASMCs) were from the American Type Culture Collection and were cultured in SMC medium (SclenCell, USA) containing 2% fetal bovine serum, 1% SMC growth supplement, 100 U/ml penicillin and 10 mg/ml streptomycin. Cells at 80% confluence from passages 4 to 6 were used. After 24-hr serum starvation, cells seeded in 6-wells were divided into 5 groups: a control group that received no drug stimulation, a no treatment group that received only stimulation of Ang II (10 -7 mol/L), a low-dose Ang IV group that received treatment of Ang II (10 -7 mol/L) + Ang IV (10 -9 mol/L), a medium-dose Ang IV group that received treatment of Ang II (10 -7 mol/L) + Ang IV (10 -7 mol/L), and a high-dose Ang IV group that received treatment of Ang II (10 -7 mol/L) + Ang IV (10 -5 mol/L) 7, 8 . To further study the role of Akt signaling in the effect of Ang IV against Ang II, cells were cultivated with Akt inhibitor A6730 (10 μmol/L, Sigma-Aldrich Company, St. Louis, MA, USA) for 1 hr before adding Ang II (10 -7 mol/L) and Ang IV (10 -9 mol/L), and were harvested after a further 24-hr stimulation.
To study the interaction of Ang IV with AT 1 R in the absence of Ang II stimulation, cells were seeded in 6-wells after serum starvation for 24 hrs and were divided into four groups that received no drug stimulation, a low-dose was used to determine relative gene expression levels. Briefly, the extracted mRNA was dissolved in RNase free water, and concentrations of the total RNA were tested using a spectrophotometer. One microgram of mRNA was used for reverse transcription using an iScript cDNA synthesis kit (Bio-Rad, USA) containing a mixture of oligo (dT) and random primers. Amplification was performed using an iCycler iQ real-time PCR detection system; the program ran for 40 cycles at 95°C for 5 seconds, 58°C for 10 seconds, and 72°C for 30 seconds. The primer sequences were presented in Table S3 .
Western blot analysis
Total proteins were extracted from the suprarenal aortas of ApoE -/-mice or hSMCs. Western blot was performed according to standard protocols, with 10% sodium dodecyl sulfate-polyacrylamide gel (SDS/PAGE), and soluble protein was transferred to nitrocellulose membranes, which were incubated with primary antibodies including rabbit β-actin antibody (1:1000, Cell Signaling Technology, USA), rabbit MMP-2 antibody (1:1000, Abcam, Hong Kong), rabbit MMP-9 antibody (1:1000, Abcam, Hong Kong), rabbit IL-6 antibody (1:1000, Abcam, Hong Kong), rabbit MCP-1 antibody (1:1000, Abcam, Hong Kong), rabbit intercellular adhesion molecule 1 (ICAM-1) antibody (1:500, Abcam, Hong Kong), rabbit type I collagen antibody (1:500, Abcam, UK), rabbit type III collagen antibody (1:500, Abcam, UK), rabbit AT 1 R antibody (1:1000, Abcam, Hong Kong), rabbit AT 2 R antibody (1:500, Abcam, Hong Kong), rabbit AT 4 R antibody (1:500, Cell Signaling Technology, MA, USA), rabbit phosphorylated Akt (p-Akt) antibody (1:1000, Cell Signaling Technology, MA, USA), rabbit Akt antibody (1:1000, Cell Signaling Technology, MA, USA), rabbit nuclear factor κB antibody (NF-κB p65, 1:1000, Cell Signaling Technology, MA, USA). Specific conjugated peroxidase-labeled secondary antibodies were used to detect primary antibodies, and the immunoreactive bands were visualized by ECL reagents (Millipore Corp., MA, USA). Protein expression levels were determined by densitometry. All experiments were repeated for three times and the mean values derived. Zymography Zymography was performed by use of a MMP gelatin zymography kit (GenMed Scientific Inc., USA). Briefly, aortic protein extracts (30 mg) from mice without boiling were separated by 10% SDS-PAGE polymerized in the presence of 0.1% gelatin to measure the activities of MMP-2 and MMP-9. Gels were washed with renaturing buffer for 2 hr and further incubated with developing buffer at 37°C for 20 hr. After incubation, gels were stained with Coomassie Brilliant Blue, and then destained with destaining buffer until clear white bands appeared on the blue background. Gel images were captured by use of a Kodak Imager (Eastman Kodak Company, New York, USA), and the unstained, translucent digested regions represented areas of MMP activity.
Multiple reaction monitoring mass spectrum (MRM-MS) technique
To clarify whether exogenously infused Ang II may be catalyzed into Ang IV in the mouse circulation, the serum Ang IV concentration was monitored using MRM-MS technique in 15 mice (5 mice from the control group, the no treatment group and the medium-dose Ang IV group, respectively). Serum Aliquots of serum were added in Microcon devices YM-10 (Millipore). The device was centrifuged at 12,000 g at 4°C for 30 min. All following centrifugation steps were preformed under the same conditions. The concentrate was diluted with 300µL deionized water and the device centrifuged. Subsequently, 300µL of 50 mM ammonium bicarbonate were added to the concentrate followed by centrifugation. The combined filtrates were desalted on Symmetry C18 (Waters, Delaware, USA). The peptide content was lyophilized and stored at -80 °C until use.
200µg heavy isotope-labeled peptide was ordered from BANKPEPTIDE LTD (Hefei, China). Each sample was dissolved using 40µL of standard 2 fmol/µL heavy isotope-labeled peptide solution. MRM experiments were performed on a 6500 QTRAP hybrid triple quadrupole/linear ion trap mass spectrometer (AB Sciex, Foster City, CA) interfaced with an Eksigent nano 1D plus system (Waters, Milford, MA). 10 µL of tryptic digests were injected using the partial loop injection mode onto a UPLC Symmetry trap column (180 µm i.d. x 2 cm packed with 5 µm C18 resin; Waters) and then separated by RP-HPLC on a column (75 µm i.d.) packed in-house with 15 cm of Magic C18 3µm reversed-phase resin (Michrom Bioresources, Auburn, CA). Chromatography was performed with Solvent A (Milli-Q (Millipore, Billerica, MA) water with 2% acetonitrile and 0.1% formic acid) and Solvent B (90% acetonitrile with 0.1% formic acid). Peptides were eluted at 300 nL/min for 5% B for 3min, 5-10% B over 5 min, 10-15% B over 27 min, 15-40% B over 35 min, 40-80% B over 1 min, 80% B for 5 min before returning to 5% B over 15 min. MRM data were acquired with a Ionspray voltage of 2,100 V, curtain gas of 20 p.s.i. Declustering potential value was predicted by SKYLINE. Pause between MS was 5ms. MRM transitions were monitored using unit resolution in both Q1 and Q3 quadrupoles to maximize specificity. Data analysis were performed using SKYLINE (version 2.6).
Statistical analysis
Statistical analyses involved use of SPSS 16.0 (SPSS Inc, Chicago, IL). Tables   Table S1. 
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